Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9475667rdf:typepubmed:Citationlld:pubmed
pubmed-article:9475667lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:9475667lifeskim:mentionsumls-concept:C0205474lld:lifeskim
pubmed-article:9475667lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:9475667lifeskim:mentionsumls-concept:C0005938lld:lifeskim
pubmed-article:9475667lifeskim:mentionsumls-concept:C0537670lld:lifeskim
pubmed-article:9475667lifeskim:mentionsumls-concept:C0085268lld:lifeskim
pubmed-article:9475667lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:9475667pubmed:issue1lld:pubmed
pubmed-article:9475667pubmed:dateCreated1998-3-26lld:pubmed
pubmed-article:9475667pubmed:abstractTextInterleukin (IL)-11 stimulates osteoclast formation and inhibits osteoblast function in vitro and has been implicated in estrogen deficiency-induced bone loss. Herein we report the in vivo effect of recombinant human IL-11 (rHU-IL-11), administered s.c. in doses between 10 and 200 microg/kg/day for 6 weeks into 6-month-old rats after ovariectomy. There was no difference between vehicle-treated and rHu-IL-11 treated rats in the ovariectomy-induced increase in the urinary excretion of pyridinoline and deoxypyridinoline. Neither was there a significant effect of rHu-IL-11 on the plasma concentrations of osteocalcin and on bone mineral density (BMD) measured at a metaphyseal area of the distal femur after 6 weeks. At all dosages tested, rHu-IL-11 increased the femoral diaphyseal area. In conclusion, IL-11 has no deleterious in vivo effect on biochemical parameters of bone remodeling and BMD in estrogen-deficient rats.lld:pubmed
pubmed-article:9475667pubmed:languageenglld:pubmed
pubmed-article:9475667pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:citationSubsetIMlld:pubmed
pubmed-article:9475667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9475667pubmed:statusMEDLINElld:pubmed
pubmed-article:9475667pubmed:monthJanlld:pubmed
pubmed-article:9475667pubmed:issn1079-9907lld:pubmed
pubmed-article:9475667pubmed:authorpubmed-author:BouillonRRlld:pubmed
pubmed-article:9475667pubmed:authorpubmed-author:DequekerJJlld:pubmed
pubmed-article:9475667pubmed:authorpubmed-author:VerhaegheJJlld:pubmed
pubmed-article:9475667pubmed:authorpubmed-author:Van HerckEElld:pubmed
pubmed-article:9475667pubmed:authorpubmed-author:KeithJ CJCJrlld:pubmed
pubmed-article:9475667pubmed:authorpubmed-author:van BreeRRlld:pubmed
pubmed-article:9475667pubmed:issnTypePrintlld:pubmed
pubmed-article:9475667pubmed:volume18lld:pubmed
pubmed-article:9475667pubmed:ownerNLMlld:pubmed
pubmed-article:9475667pubmed:authorsCompleteYlld:pubmed
pubmed-article:9475667pubmed:pagination49-53lld:pubmed
pubmed-article:9475667pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:meshHeadingpubmed-meshheading:9475667-...lld:pubmed
pubmed-article:9475667pubmed:year1998lld:pubmed
pubmed-article:9475667pubmed:articleTitleRecombinant human interleukin-11 does not modify biochemical parameters of bone remodeling and bone mineral density in adult ovariectomized rats.lld:pubmed
pubmed-article:9475667pubmed:affiliationDepartment of Obstetrics and Gynecology, Bone Disease Research Unit, Katholieke Universiteit Leuven, Belgium.lld:pubmed
pubmed-article:9475667pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9475667pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9475667pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed